Time: 2024-12-16
fleshiness in the United States has see a rebuff decrease after over a decade, with the most significant drop detect in the South region. This shift has been impute to the rise of weight-loss drug such as Ozempic and Wegovy, particularly among adult aged 66 to 75 and woman. The findings were recently print in the diary JAMA Health Forum, analyze data from More than 16 million adult between the age of 26 and 75 over a 10-year period.
harmonize to research_worker, distribute rates of GLP-1 receptor protagonist, include Semaglutide, were high in the South. These drug are commonly use in Weight loss medicine. However, it is necessity to note that distribute rates do not necessarily correlate with actual consumption. The South also experience a disproportionately high COVID-19 mortality rate among person with fleshiness, as foreground by the writer of the research.
The survey show that fleshiness prevalence in U.S. adult decrease from 46% in 2022 to 45.6% in 2023. Notably, the decline was most outstanding in the South, although variation were detect among different demographic group and geographic region. While the survey bespeak a positive tendency in fleshiness decrease, expert stress the need for foster probe and hanker-term survey to fully understand the impact of weight loss medications.
Although weight loss drug like Ozempic have show promise in battle fleshiness, expert caution that More research is necessity to measure their hanker-term effectiveness. While the use of GLP-1 drug has lend to the decline in fleshiness, it is crucial to see other factor that may influence these tendency. Additionally, the cost and handiness of weight loss medicine may skew data on who can entree treatment.
Despite the promise consequence bespeak a potential shift in the fleshiness epidemic, expert stay timid about label the decrease in fleshiness prevalence as a hanker-term tendency. previous fluctuation in fleshiness rates have show that detect dip may not always translate to prolong decline. Therefore, continuous monitoring and research are necessity to determine the true impact of anti-fleshiness medicine and other factor on the overall fleshiness rates in the United States.